BrainChild-01

**BrainChild-01** is an investigational autologous CAR T-cell therapy developed by Seattle Children's for relapsed or refractory HER2-positive pediatric central nervous system (CNS) tumors, such as medulloblastoma, ependymoma, and glioma (excluding DIPG). It involves reprogramming a patient's own CD4+ and CD8+ T cells via lentiviral transduction to express a HER2-specific chimeric antigen receptor (CAR), which targets and destroys HER2-expressing tumor cells while sparing healthy brain tissue. The therapy is administered locoregionally through an indwelling catheter directly into the CNS resection cavity or ventricular system to bypass the blood-brain barrier, enabling repeated doses with potentially reduced systemic toxicity like cytokine release syndrome.[1][2][3][4][13]

Other names

HER2-specific chimeric antigen receptor T cellHER-2-specific chimeric antigen receptor T cellHER 2-specific chimeric antigen receptor T cellHER2-CAR T cellsHER-2-CAR T cellsHER 2-CAR T cellsHER2-specific CAR T cellsHER-2-specific CAR T cellsHER 2-specific CAR T cells